180 related articles for article (PubMed ID: 26273818)
1. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
[TBL] [Abstract][Full Text] [Related]
2. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
[TBL] [Abstract][Full Text] [Related]
5. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
[TBL] [Abstract][Full Text] [Related]
6. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
[TBL] [Abstract][Full Text] [Related]
8. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis.
Liaskos C; Spyrou V; Athanasiou LV; Orfanidou T; Mavropoulos A; Rigopoulou EI; Amiridis GS; Shoenfeld Y; Billinis C; Bogdanos DP
Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):384-90. PubMed ID: 25575461
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
[TBL] [Abstract][Full Text] [Related]
10. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
[TBL] [Abstract][Full Text] [Related]
12. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
[TBL] [Abstract][Full Text] [Related]
13. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
[TBL] [Abstract][Full Text] [Related]
15. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
Pavlidis P; Romanidou O; Roggenbuck D; Mytilinaiou MG; Al-Sulttan F; Liaskos C; Smyk DS; Koutsoumpas AL; Rigopoulou EI; Conrad K; Forbes A; Bogdanos DP
Clin Dev Immunol; 2012; 2012():640835. PubMed ID: 23118780
[TBL] [Abstract][Full Text] [Related]
16. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
[TBL] [Abstract][Full Text] [Related]
17. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.
Liaskos C; Spyrou V; Roggenbuck D; Athanasiou LV; Orfanidou T; Mavropoulos A; Reinhold D; Rigopoulou EI; Amiridis GS; Billinis C; Bogdanos DP
Autoimmunity; 2013 Sep; 46(6):388-94. PubMed ID: 23638886
[TBL] [Abstract][Full Text] [Related]
18. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
[TBL] [Abstract][Full Text] [Related]
19. Serological studies in inflammatory bowel disease: how important are they?
Papp M; Lakatos PL
Curr Opin Gastroenterol; 2014 Jul; 30(4):359-64. PubMed ID: 24811052
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
